Vicente LLP Federal and International Cannabis and Psychedelics Law and Policy Update: November 2023
Nov 10, 2023
Federal and international law and policy insights, news and events from Vicente LLP.
Nov 10, 2023
Federal and international law and policy insights, news and events from Vicente LLP.
By Shawn Hauser
Aug 31, 2023
The federal government formally acknowledged the medical use and low potential of abuse for cannabis, with the US Department of Health and Human Services recommending that cannabis be rescheduled to Schedule III under the Controlled Substances Act. While placement in Schedule III still criminalizes commercial cannabis activity at the federal level, it is a significant step on the path to ending prohibition. This rescheduling would eliminate the application of 280E tax penalties, reduce the level of criminal liability for cannabis-related activity, reduce barriers to research, legitimize the industry through gaining credibility and engagement by physicians and the medical community, and support a growing industry for the American economy.
By Shane Pennington
Apr 4, 2023
Cannabis researchers can study the dispensary strains and products people are actually using around the country right now... without violating federal law… and without Congress lifting a finger. Read this article for two simple tricks to do so.
By Shane Pennington
Mar 1, 2023
How TGA's rescheduling of psilocybin and MDMA shines a bright light on DEA delinquency
Jan 19, 2023
Join Shane Pennington on February 1 for a Cannabis Business Times webinar discussing the opportunities and challenges surrounding the federally legal cannabis seeds market.
By Shane Pennington
Nov 9, 2022
What outcomes are possible from the impending administrative process to reconsider cannabis’s schedule I status? What are the implications of those various possible outcomes? And how should we all proceed in light of it all?
By Shane Pennington
Oct 21, 2022
To appreciate the gravity of the President’s scheduling directive and what could happen next, you need to understand (1) how the administrative process the President has set in motion will actually work and (2) how the agencies in charge have used it to affirm and reaffirm cannabis’s schedule I1 status repeatedly throughout the Comprehensive Drug Abuse Prevention and Control Act of 1970’s (“CSA”) history. Those topics are covered in this article.
By Shane Pennington
Oct 21, 2022
President Biden’s scheduling directive is enormously important. In fact, if permitted to run its course, it could revolutionize federal drug control law to a far greater degree than any of the many pending cannabis legalization bills.
Jul 28, 2022
Update on hemp-related legislation and rulemaking, regulatory changes, and other noteworthy hemp news and events.
Apr 14, 2022
Update on the lawsuit HIA & RE Botanicals, Inc v. DEA and why this case is critical to the hemp industry's future.
Apr 4, 2022
Update on hemp-related legislation and rulemaking, regulatory changes, and other noteworthy hemp news and events.
By Shane Pennington
Nov 4, 2021
The NIDA monopoly on cultivating cannabis for research ended in May 2021. Researchers can now study cannabis from state-legal markets by getting it from one of DEA's newly-licensed cannabis cultivators.
By Shane Pennington
Oct 18, 2021
An introduction to the different registrations available for schedule I substances such as psilocybin and psilocin.
Aug 25, 2021
Vote for the panel "Sue 'n the DEA: Breaking the 50-Year NIDA Monopoly," featuring Shane Pennington to be included in SXSW 2022!
Aug 25, 2021
Vote for the panel "Sue 'n the DEA: Breaking the 50-Year NIDA Monopoly," featuring Shane Pennington to be included in SXSW 2022!